Clinical evaluation of haloprogin.
D000480:Alkynes / Q000627:therapeutic use / Q000633:toxicity; D000935:Antifungal Agents / Q000627:therapeutic use* / Q000633:toxicity; D002175:Candida / Q000187:drug effects; D002247:Carbon Isotopes; D002986:Clinical Trials as Topic; D003881:Dermatomycoses / Q000188:drug therapy; D003875:Drug Eruptions / Q000209:etiology; D006801:Humans; D007455:Iodine / Q000627:therapeutic use / Q000633:toxicity; D010636:Phenols / Q000627:therapeutic use* / Q000633:toxicity; D012869:Skin Absorption; D014008:Tinea Pedis / Q000188:drug therapy; D014047:Tolnaftate / Q000627:therapeutic use; D014249:Trichophyton / Q000187:drug effects
D000480:Alkynes; D000935:Antifungal Agents; D002247:Carbon Isotopes; D010636:Phenols; D014047:Tolnaftate; D007455:Iodine